Last reviewed · How we verify

NCT06587087

A Proof of Concept (PoC), Randomized, Controlled Study to Validate the Algorithm and Evaluate the Accuracy, Safety and Pain Level of the Smartest-AE in Comparison to Self-measure Blood Glucose Levels

Not yet recruiting NA Last updated 19 September 2024
What this trial tests

NA trial testing Smartest-AE: The lancet that will be used will be the Vitrex Soft Lite lll 28G. in Diabetes Mellitus in 300 participants. Not yet recruiting.

Timeline
20 September 2024
Primary endpoint
31 January 2025
15 February 2025

Quick facts

Lead sponsorSmartest Technologies
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposescreening
Enrollment300
Start date20 September 2024
Primary completion31 January 2025
Estimated completion15 February 2025
Sites1 location across Israel

Drugs / interventions tested

Conditions studied

Sponsor

Smartest Technologies

Who can join

Adults 18 to 80, any sex, with Diabetes Mellitus or Gestational Diabetes Mellitus (GDM). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is conducted in Israel so plain language for the study is exist in Hebrew only

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06587087.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing